Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Bruno P Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto & Francesco Panza. (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Review of Clinical Immunology 8:2, pages 135-149.
Read now
Read now
Francesco Panza, Vincenza Frisardi, Bruno P Imbimbo, Davide Seripa, Vincenzo Solfrizzi & Alberto Pilotto. (2011) Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. Expert Opinion on Biological Therapy 11:6, pages 679-686.
Read now
Read now
Refik Pul, Richard Dodel & Martin Stangel. (2011) Antibody-based therapy in Alzheimer's disease. Expert Opinion on Biological Therapy 11:3, pages 343-357.
Read now
Read now
Geoffrey A Kerchner & Adam L Boxer. (2010) Bapineuzumab. Expert Opinion on Biological Therapy 10:7, pages 1121-1130.
Read now
Read now
Articles from other publishers (23)
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer & Randall J. Bateman. (2022) Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer's Research & Therapy 14:1.
Crossref
Crossref
Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer & Jeffrey L. Cummings. (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Research & Therapy 13:1.
Crossref
Crossref
Stefan Bartl, Abid Oueslati, Amber L. Southwell, Alberto Siddu, Michela Parth, Linda Suzanne David, Alexander Maxan, Nina Salhat, Markus Burkert, Andreas Mairhofer, Theresa Friedrich, Halyna Pankevych, Katja Balazs, Guenther Staffler, Michael R. Hayden, Francesca Cicchetti & Oskar W. Smrzka. (2020) Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of Disease 141, pages 104943.
Crossref
Crossref
Paul J. Derry, Muralidhar L. Hegde, George R. Jackson, Rakez Kayed, James M. Tour, Ah-Lim Tsai & Thomas A. Kent. (2020) Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. Progress in Neurobiology 184, pages 101716.
Crossref
Crossref
Marie Rieux, Melanie Alpaugh & Francesca Cicchetti. (2018) The troubling story of blood-driven dementias. Molecular Psychiatry 24:2, pages 162-166.
Crossref
Crossref
Veronika Logovinsky, Andrew Satlin, Robert Lai, Chad Swanson, June Kaplow, Gunilla Osswald, Hans Basun & Lars Lannfelt. (2016) Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer's Research & Therapy 8:1.
Crossref
Crossref
Antonio Francioso, Pasqualina Punzi, Alberto Boffi, Clorinda Lori, Sara Martire, Cesare Giordano, Maria D’Erme & Luciana Mosca. (2015) β-Sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis. Bioorganic & Medicinal Chemistry 23:8, pages 1671-1683.
Crossref
Crossref
Arne Ittner, Josefine Bertz, Lisa S. Suh, Claire H. Stevens, Jürgen Götz & Lars M. Ittner. (2015) Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. Journal of Neurochemistry 132:1, pages 135-145.
Crossref
Crossref
Rajesh S. Omtri, Michael W. Davidson, Balasubramaniam Arumugam, Joseph F. Poduslo & Karunya K. Kandimalla. (2012) Differences in the Cellular Uptake and Intracellular Itineraries of Amyloid Beta Proteins 40 and 42: Ramifications for the Alzheimer’s Drug Discovery. Molecular Pharmaceutics 9:7, pages 1887-1897.
Crossref
Crossref
Francesco PanzaVincenza Frisardi, Bruno P Imbimbo, Giancarlo Logroscino, Davide Seripa, Alberto Pilotto & Vincenzo Solfrizzi. (2012) Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients. Future Neurology 7:4, pages 395-401.
Crossref
Crossref
Rob J. A. Nabuurs, Kim S. Rutgers, Mick M. Welling, Athanasios Metaxas, Maaike E. de Backer, Maarten Rotman, Brian J. Bacskai, Mark A. van Buchem, Silvère M. van der Maarel & Louise van der Weerd. (2012) In Vivo Detection of Amyloid-β Deposits Using Heavy Chain Antibody Fragments in a Transgenic Mouse Model for Alzheimer's Disease. PLoS ONE 7:6, pages e38284.
Crossref
Crossref
Francesco PanzaVincenza Frisardi, Vincenzo Solfrizzi, Bruno P Imbimbo, Giancarlo Logroscino, Andrea Santamato, Antonio Greco, Davide Seripa & Alberto Pilotto. (2012) Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4:2, pages 213-238.
Crossref
Crossref
Jennifer D. Lanning & Stephen C. Meredith. 2012. Non-fibrillar Amyloidogenic Protein Assemblies - Common Cytotoxins Underlying Degenerative Diseases. Non-fibrillar Amyloidogenic Protein Assemblies - Common Cytotoxins Underlying Degenerative Diseases
433
560
.
Pavan K. Krishnamurthy & Einar M. Sigurdsson. (2011) Therapeutic applications of antibodies in non-infectious neurodegenerative diseases. New Biotechnology 28:5, pages 511-517.
Crossref
Crossref
Yulia Vugmeyster, Pam Szklut, David Wensel, John Ross, Xin Xu, Michel Awwad, Davinder Gill, Lioudmila Tchistiakov & Garvin Warner. (2011) Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species. Pharmaceutical Research 28:7, pages 1696-1706.
Crossref
Crossref
Francesco Panza, Vincenza Frisardi, Bruno P Imbimbo, Grazia D’Onofrio, Giuseppe Pietrarossa, Davide Seripa, Alberto Pilotto & Vincenzo Solfrizzi. (2010) Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy 2:6, pages 767-782.
Crossref
Crossref
Ravindra Kodali, Angela D. Williams, Saketh Chemuru & Ronald Wetzel. (2010) Aβ(1–40) Forms Five Distinct Amyloid Structures whose β-Sheet Contents and Fibril Stabilities Are Correlated. Journal of Molecular Biology 401:3, pages 503-517.
Crossref
Crossref
M. Buttmann & H. Wiendl. (2010) Therapeutische monoklonale Antikörper in der NeurologieTherapeutic monoclonal antibodies in clinical neurology. Der Nervenarzt 81:6, pages 753-766.
Crossref
Crossref
Manuela Bartolini & Vincenza Andrisano. (2010) Strategies for the Inhibition of Protein Aggregation in Human Diseases. ChemBioChem 11:8, pages 1018-1035.
Crossref
Crossref
Ruben J. Boado, Jeff Zhiqiang Lu, Eric Ka‐Wai Hui & William M. Pardridge. (2009) IgG‐single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnology and Bioengineering 105:3, pages 627-635.
Crossref
Crossref
Alan M. Palmer. (2010) The role of the blood–CNS barrier in CNS disorders and their treatment. Neurobiology of Disease 37:1, pages 3-12.
Crossref
Crossref
. (2009) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 24:11.
Crossref
Crossref
Jason Pitt, William Roth, Pascale Lacor, Amos B. SmithIIIIII, Matthew Blankenship, Pauline Velasco, Fernanda De Felice, Paul Breslin & William L. Klein. (2009) Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicology and Applied Pharmacology 240:2, pages 189-197.
Crossref
Crossref